SEC Form 4
------------

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL MB Number: 3235-028

OMB Number:	3235-0287
Estimated average b	ourden
hours per response:	0.5

Instruction 1(b).		Filed pursuant to Section 16(a) of the Securities Exchange Act of 19	34			
		or Section 30(h) of the Investment Company Act of 1940				
1. Name and Address of	1 0	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Medpace Holdings, Inc.</u> [MEDP]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
<u>Troendle August J.</u>		<u> </u>	X Director X 10% Owner			
			Officer (give title Other (specify			
(Last) (F	irst) (Middle)	3. Date of Earliest Transaction (Month/Day/Year)	below) below)			
C/O MEDPACE H	OLDINGS, INC.	07/15/2020	President & CEO			
5375 MEDPACE V	VAY					
		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable			
(Street)			Line)			
CINCINNATI O	H 45227		X Form filed by One Reporting Person			
			Form filed by More than One Reporting Person			
(City) (S	State) (Zip)					

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Table 1 - Non-Derivative Securities Acquired, Disposed 01, 01 Beneficially Owned										
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)				5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	- Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock								616,643	D	
Common Stock	07/15/2020		S <sup>(1)</sup>		28,700(1)	D	\$104.9(2)	7,753,484	I	By Medpace Investors, LLC <sup>(3)</sup>
Common Stock	07/16/2020		S <sup>(1)</sup>		15,273 <sup>(1)</sup>	D	\$103.7(4)	7,738,211	Ι	By Medpace Investors, LLC <sup>(3)</sup>

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 3A. Deemed 1. Title of Derivative 2 3. Transaction 5. Number 6. Date Exercisable and 7. Title and 8. Price of 9. Number of 10. 11. Nature Conversion Ownership Date Execution Date Transaction of Expiration Date Amount of Derivative derivative of Indirect Derivative Security or Exercise (Month/Dav/Year) if any Code (Instr. (Month/Day/Year) Securities Security Securities Form: Beneficial (Instr. 3) Price of (Month/Day/Year) 8) Securities Underlying (Instr. 5) Beneficially Direct (D) Ownership Derivative Acquired Derivative Owned or Indirect (Instr. 4) Security (A) or Disposed Security (Instr. 3 and 4) Following Reported (I) (Instr. 4) of (D) (Instr. 3, 4 and 5) Transaction(s) (Instr. 4) Amount or Number Expiration Date Date v (D) Title Code (A) Exercisable Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020.

2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$101.48 to \$106.305. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

3. The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

4. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$103.16 to \$105. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

<u>/s/ Stephen P. Ewald,</u> <u>Attorney-in-Fact for August J.</u> 07/17/2020 <u>Troendle</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See